Tuesday, French drugmaker Sanofi SA (NASDAQ: SNY) announced its collaboration with OpenAI and Formation Bio to accelerate drug development projects.
Sanofi said the partnership with OpenAI will allow it to access proprietary data to develop AI models for its biopharma models, while Formation Bio will provide additional engineering resources.
The three teams will combine data, software, and tuned models to develop custom, purpose-built solutions for the drug development lifecycle.
OpenAI will contribute access to AI capabilities, including the ability to fine-tune models, deep AI expertise, and dedicated thought partnerships and resources.
Formation Bio, an AI and tech-driven drug developer with its pipeline of drug assets, will provide engineering resources, experience operating at the intersection of pharma and AI, and its tech-driven development platform to design, develop, and deploy AI technologies across all aspects of the pharma lifecycle.
The potential benefits of AI for patients awaiting new treatments are immense, and Sanofi, Formation Bio, and OpenAI aim to set the standard for drug developers.
Last month, Moderna Inc (NASDAQ: MRNA) and Microsoft Corp (NASDAQ: MSFT) -backed OpenAI announced their ongoing collaboration to co-innovate.
Moderna began a collaboration with OpenAI in early 2023 with the launch of Moderna's own instance of ChatGPT, called mChat. The company announced Wednesday that it has reached more than 80% internal adoption of mChat, which has accelerated the AI culture at Moderna.
Price Action: SNY shares are down 0.62% at $48.12 during the premarket session at last check Tuesday.